AT8 Antibody

What is the phosphoepitope specificity of the AT8 antibody, and how is it validated?

The AT8 antibody recognizes tau phosphorylated at Ser202 and Threonine 205 (pS202/pT205) . Advanced epitope mapping using phosphopeptide ELISA, surface plasmon resonance (SPR), and X-ray crystallography confirmed that AT8 also requires phosphorylation at Ser208 (pS202/pT205/pS208) for optimal binding . Structural studies revealed that pT205 acts as an anchor residue, while pS202 and pS208 stabilize interactions with complementarity-determining regions (CDRs) of the antibody .
Validation methodologies include:

• Competitive ELISA: Testing binding to synthetic tau peptides with single/double/triple phosphorylation .

• ProteOn affinity assays: Measuring dissociation constants (e.g., K_D = 31 nM for triply phosphorylated peptides vs. 5.4 μM for diphosphorylated variants) .

• Immunohistochemistry (IHC): Confirming reactivity with pathological tau in Alzheimer’s disease (AD) brain sections .

What are the primary applications of AT8 in neurodegenerative disease research?

AT8 is widely used to detect hyperphosphorylated tau in:

• Neuropathological staging: Identifying pretangles and neurofibrillary tangles in AD brain tissues .

• Biochemical assays: Quantifying phosphorylated tau (p-tau) in cerebrospinal fluid (CSF) or plasma via ELISA (e.g., INNOTEST® platform) .

• In vitro models: Monitoring tau phosphorylation in cell lines treated with kinase inhibitors or Aβ oligomers .

Example protocol for IHC:

• Fix tissue sections with 4% paraformaldehyde.

• Block with 2% BSA + 0.1% Triton X-100.

• Incubate with AT8 (1:100 dilution) at 4°C overnight .

• Detect using Alexa Fluor-conjugated secondary antibodies .

How does AT8 compare to other phospho-tau antibodies in specificity?

AT8 exhibits high specificity for pS202/pT205/pS208 but shows weak cross-reactivity with pS199/pS202 or pT205/pS208 peptides . A comparative analysis using flow cytometry-derived specificity parameter Φ (phi) revealed:

Key validation steps:

• HEK293FT transfection: Co-expressing human tau with kinases (e.g., GSK3β) to mimic phosphorylation .

• Western blot: Confirming absence of off-target bands in tau-knockout models .

How do phosphorylation heterogeneity and conformational changes impact AT8 binding in experimental models?

AT8’s affinity varies significantly with phosphorylation stoichiometry:

• Triply phosphorylated tau (pS202/pT205/pS208): K_D = 31 nM .

• Doubly phosphorylated tau (pS202/pT205): K_D = 1.1 μM .

This heterogeneity complicates data interpretation in AD models, as tau aggregates contain mixed phosphorylation states . Mitigation strategies:

• Dephosphorylation controls: Treat samples with alkaline phosphatase to abolish AT8 signal .

• Multi-epitope validation: Combine AT8 with antibodies targeting adjacent sites (e.g., AT180 for pT231) .

What structural features of AT8 enable its specificity for pathological tau?

X-ray crystallography of AT8 Fab bound to pS202/pT205/pS208 peptide revealed:

• Paratope architecture: All six CDRs participate in binding, with CDR-H3 forming hydrogen bonds to pT205 .

• Phosphate coordination:

  • pS202: Salt bridge with Arg50 (light chain) .

  • pT205: Hydrogen bonds with Tyr32 and Ser52 (heavy chain) .

  • pS208: Stabilizes a β-turn structure in the peptide .

Implications for assay design:

• Acidic buffers (pH < 5.0) disrupt CDR-L2 conformation, reducing binding affinity .

• Use neutral pH buffers (e.g., PBS) for consistent results .

How can AT8-based assays be integrated with emerging technologies for p-tau quantification?

High-sensitivity platforms leveraging AT8:

Optimization tips:

• Pair AT8 with non-overlapping antibodies: For sandwich ELISA, use AT8 (capture) with HT7 (detection) .

• Signal amplification: Employ rolling circle amplification (RCA) for ultralow-abundance p-tau in plasma .

What are the limitations of AT8 in preclinical research, and how can they be addressed?

Key limitations:

• Species cross-reactivity: Fails to bind bovine or rodent tau due to sequence divergence at residues 199–209 .

• Epitope masking: Phosphorylation at adjacent sites (e.g., pS199) reduces accessibility .

Solutions:

• Transgenic models: Use mice expressing human tau isoforms (e.g., hTau.P301S) .

• Multiplex assays: Combine AT8 with phosphorylation-independent antibodies (e.g., Tau5) to normalize signal .

How do post-translational modifications (PTMs) beyond phosphorylation affect AT8 binding?

While AT8 is phosphorylation-specific, other PTMs may indirectly modulate its epitope:

• Acetylation at K174: Alters tau’s conformational flexibility, reducing AT8 binding in in vitro aggregates .

• O-GlcNAcylation near S202: Competes with phosphorylation, as shown by mass spectrometry .

Experimental workflow to study PTM crosstalk:

• Treat tau-expressing HEK cells with Thiamet-G (OGA inhibitor).

• Quantify AT8 signal via flow cytometry .

• Validate using LC-MS/MS to map modification sites .

Methodological Best Practices

• Storage: Aliquot AT8 in PBS (pH 7.4) at -80°C; avoid freeze-thaw cycles .

• Controls: Include non-phosphorylated tau and phosphatase-treated samples in every assay .

• Troubleshooting low signal: Pre-treat tissues with formic acid to expose epitopes in fixed samples .